Skip to content

Cerus CERS Additional Paid-In Capital

Additional Paid-In Capital at other companies

CorMedix logo
CorMedixCRMD
$574.94M+32.6%
Haemonetics logo
HaemoneticsHAE
$554.14M+5.9%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.12B+7.8%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$2.94B+1.6%
ADMA Biologics logo
ADMA BiologicsADMA
$649.8M-0.8%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's additional paid-in capital?
Cerus (CERS) reported additional paid-in capital of $1.15B in Q1 2026.
How has Cerus's additional paid-in capital changed year-over-year?
Cerus's additional paid-in capital increased by 1.9% year-over-year, from $1.13B to $1.15B.
What is the long-term trend for Cerus's additional paid-in capital?
Over 5 years (2020 to 2025), Cerus's additional paid-in capital has grown at a 2.5% compound annual growth rate (CAGR), from $1.01B to $1.15B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.